Upexi Regains Compliance with NASDAQ

Rhea-AI Summary

Upexi (NASDAQ:UPXI) has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its financial results for the fiscal year ended June 30, 2024, and first quarter ending September 30, 2024. The company has completed several critical restructuring transactions, resulting in significant debt reduction and increased working capital.

Key operational developments include the successful sale of stakes in Interactive Offers, VitaMedica, and E-Core Technology, along with a building sale. Upexi maintains fully operational manufacturing and distribution facilities in Odessa and Tampa, Florida, with Gumi Labs operating at full capacity since August 2024. The company continues to market its portfolio of brands including LuckyTail, PRAX, Cure Mushrooms, and Moonwlkr.

Positive

• Regained Nasdaq compliance
• Significant debt reduction through restructuring
• Increased working capital position
• Manufacturing facilities operating at full capacity
• Successfully completed multiple asset sales

Negative

• Required restructuring process indicates previous financial difficulties
• Divestment of multiple business units suggests operational downsizing

Insights

Financial Restructuring Analyst

The regaining of NASDAQ compliance coupled with significant restructuring efforts marks a critical turning point for Upexi. The company's strategic divestitures of Interactive Offers, VitaMedica and E-Core Technology, along with a building sale, demonstrate a focused approach to debt reduction and working capital optimization. Operating at full manufacturing capacity since August 2024 in Florida facilities signals operational efficiency. The retention of key brand assets (LuckyTail, PRAX, Cure Mushrooms, Moonwlkr) while streamlining operations suggests a more sustainable business model. For a micro-cap company with a $4.58M market value, maintaining NASDAQ listing is important for market accessibility and investor confidence. The successful completion of restructuring and debt reduction improves the company's risk profile, though careful monitoring of working capital management and operational execution remains essential given the small market capitalization.

Compliance Expert

The resolution of NASDAQ Rule 5250(c)(1) compliance issues through timely filing of the 10-K and 10-Q represents more than just regulatory adherence. For micro-cap companies, maintaining listing requirements is fundamental to market credibility and access to capital markets. The closure of these compliance matters eliminates a significant overhang that typically concerns institutional investors and could have restricted financing options. The company's ability to file both reports while executing complex restructuring transactions demonstrates improved internal controls and financial reporting capabilities. This development removes a major risk factor that often leads to delisting procedures, which can be particularly damaging for small-cap companies with trading volumes.

Filing Form 10-K for the Year Ended June 30, 2024

Filing Form 10-Q for the Quarter Ending September 30, 2024

TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic reports that the Company now complies with the Rule and accordingly these matters are now closed.

Allan Marshall, Chief Executive Officer of Upexi, stated, "We are pleased to have filed our financial results for the fiscal year ending June 30, 2024 and fiscal first quarter ending September 30, 2024. During this period, we completed several critical transactions as part of our restructuring process, which has resulted in a significant reduction in debt and increase in working capital. We have sufficient working capital to fund our operations meet our debt obligations. Going forward, we have stable and cash flowing manufacturing, distribution and fulfillment facilities in Florida as well as a portfolio of pet, health and CBD brands. We have completed the restructuring and can focus on operating our businesses and explore new opportunities for the future."

Operational Highlights:

• Successfully sold its equity interest in Interactive Offers, LLC, VitaMedica, and E-Core Technology, Inc.

• Completed sale of building.

• Upexi continues to operate its manufacturing and distribution centers in Odessa, Florida and warehousing, distribution and other services for product sales in Tampa, Florida.

• These facilities include operations by Gumi Labs, which manufactures gummies and other products, including products manufactured with hemp ingredients.

• The manufacturing facilities in Florida are operating at full capacity as of August of 2024.

• Upexi also continues to market and distribute its LuckyTail, PRAX, Cure Mushrooms, and Moonwlkr brands.

About Upexi, Inc.:

Upexi is a brand owner specializing in the development, manufacturing and distribution of consumer products.

FORWARD LOOKING STATEMENTS:

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with business strategy, potential acquisitions, revenue guidance, product development, integration, and synergies of acquiring companies and personnel. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward- looking statements. Although we believe that the beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Company Contact
Andrew Norstrud, Chief Financial Officer
Email: andrew.norstrud@upexi.com
Phone: (702) 332-5591

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
Email: Upexi@KCSA.com
Phone: (212) 896-1254

SOURCE: Upexi

View the original press release on accesswire.com

FAQ

What actions did Upexi (UPXI) take to regain Nasdaq compliance?

Upexi filed its financial results for the fiscal year ended June 30, 2024, and first quarter ending September 30, 2024, which satisfied Nasdaq Listing Rule 5250(c)(1) requirements.

What assets did Upexi (UPXI) sell during its 2024 restructuring?

During the restructuring, Upexi sold its equity interests in Interactive Offers, , VitaMedica, E-Core Technology, Inc., and a building.

When did Upexi's (UPXI) Florida manufacturing facilities reach full capacity?

Upexi's manufacturing facilities in Florida reached full operational capacity in August 2024.

What brands does Upexi (UPXI) currently maintain in its portfolio?

Upexi currently maintains and distributes LuckyTail, PRAX, Cure Mushrooms, and Moonwlkr brands.

How has the 2024 restructuring affected Upexi's (UPXI) financial position?

The restructuring resulted in significant debt reduction and increased working capital, providing sufficient funds to operate and meet debt obligations.